Qiufei Ma

548 total citations
51 papers, 301 citations indexed

About

Qiufei Ma is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Qiufei Ma has authored 51 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 14 papers in Molecular Biology and 14 papers in Hematology. Recurrent topics in Qiufei Ma's work include CAR-T cell therapy research (19 papers), Multiple Myeloma Research and Treatments (13 papers) and Lymphoma Diagnosis and Treatment (13 papers). Qiufei Ma is often cited by papers focused on CAR-T cell therapy research (19 papers), Multiple Myeloma Research and Treatments (13 papers) and Lymphoma Diagnosis and Treatment (13 papers). Qiufei Ma collaborates with scholars based in United States, United Kingdom and Germany. Qiufei Ma's co-authors include Zhongyun Zhao, Beth Barber, Hongbo Yang, Irina Yermilov, Eric Q. Wu, Julie Munakata, Junlong Li, Jie Zhang, Judy Y. Chen and Hua Chen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Qiufei Ma

39 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qiufei Ma United States 10 173 49 44 41 38 51 301
Lingling Yuan China 12 63 0.4× 234 4.8× 14 0.3× 19 0.5× 33 0.9× 32 431
Jie Guan China 9 66 0.4× 63 1.3× 9 0.2× 18 0.4× 74 1.9× 28 326
Christopher D. Clay Australia 11 163 0.9× 81 1.7× 51 1.2× 32 0.8× 18 0.5× 12 463
Afshin Rakhsha Iran 10 123 0.7× 35 0.7× 30 0.7× 8 0.2× 6 0.2× 36 280
Adam Goldman Israel 11 139 0.8× 50 1.0× 9 0.2× 7 0.2× 31 0.8× 24 350
Gaia Moretta Italy 12 31 0.2× 24 0.5× 39 0.9× 35 0.9× 275 7.2× 34 401
Tejaswi Mudigonda United States 8 109 0.6× 30 0.6× 17 0.4× 17 0.4× 91 2.4× 12 285
Adrian YS Yip China 11 106 0.6× 71 1.4× 26 0.6× 12 0.3× 31 0.8× 20 280
Lorenzo Iovino United States 10 82 0.5× 71 1.4× 70 1.6× 10 0.2× 86 2.3× 38 317
R. Izu Spain 11 69 0.4× 73 1.5× 89 2.0× 9 0.2× 107 2.8× 33 351

Countries citing papers authored by Qiufei Ma

Since Specialization
Citations

This map shows the geographic impact of Qiufei Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiufei Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiufei Ma more than expected).

Fields of papers citing papers by Qiufei Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qiufei Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiufei Ma. The network helps show where Qiufei Ma may publish in the future.

Co-authorship network of co-authors of Qiufei Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Qiufei Ma. A scholar is included among the top collaborators of Qiufei Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiufei Ma. Qiufei Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kumar, Shaji, Xavier Leleu, Katja Weisel, et al.. (2025). Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review. Clinical Lymphoma Myeloma & Leukemia. 25(10). 730–738.e11.
3.
Hoffman, James E., Naresh Bumma, Joshua Richter, et al.. (2025). Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial. Clinical Lymphoma Myeloma & Leukemia. 25. S116–S116. 1 indexed citations
4.
Jagannath, Sundar, Hans C. Lee, Joshua Richter, et al.. (2024). Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7560–7560. 1 indexed citations
5.
Zonder, Jeffrey A., Hans C. Lee, Joshua Richter, et al.. (2024). P-403 Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S267–S267. 1 indexed citations
6.
Johnson, P. Connor, et al.. (2024). Real-world evaluation of health-related quality of life in patients with diffuse large B-cell lymphoma based on a multinational survey. Frontiers in Oncology. 14. 1402992–1402992. 1 indexed citations
7.
8.
Ma, Qiufei, Thomas E. Delea, May Hagiwara, et al.. (2021). Lifetime Costs for Treated Follicular Lymphoma Patients in the US. PharmacoEconomics. 39(10). 1163–1183. 3 indexed citations
9.
Teshima, Takanori, Jie Zhang, Qiufei Ma, et al.. (2021). Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan. Transplantation and Cellular Therapy. 27(6). 506.e1–506.e10. 17 indexed citations
10.
Sun, Shengtao, et al.. (2021). A Case Report of Gemella haemolysans Keratitis After Refractive Surgery. Infection and Drug Resistance. Volume 14. 5175–5181.
11.
Broder, Michael S., Qiufei Ma, Tingjian Yan, et al.. (2020). Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.. PubMed Central. 13(5). 192–199. 7 indexed citations
12.
Fowler, Nathan, Guifang Chen, Stephen Lim, et al.. (2020). reatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma. Journal of health economics and outcomes research. 7(2). 148–157. 9 indexed citations
13.
Teshima, Takanori, Jie Zhang, Qiufei Ma, et al.. (2020). Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan. Transplantation and Cellular Therapy. 27(3). 241.e1–241.e11. 13 indexed citations
14.
Ma, Qiufei, Mark Shilkrut, Zhongyun Zhao, et al.. (2018). Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. BMC Cancer. 18(1). 145–145. 16 indexed citations
15.
Ma, Qiufei, et al.. (2016). Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.. PubMed. 9(4). 203–13. 33 indexed citations
16.
Ma, Qiufei, Zhongyun Zhao, Beth Barber, & Mark Shilkrut. (2016). Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis. Advances in Therapy. 33(2). 282–289. 7 indexed citations
17.
18.
Sun, Shengtao, Qiufei Ma, Hong Hu, et al.. (2015). [Molecular identification and in vitro susceptibility of Fusarium from fungal keratitis in central China].. PubMed. 51(9). 660–7. 6 indexed citations
19.
Ma, Qiufei, et al.. (2011). HIV Screening in Commercially Insured Patients Screened or Diagnosed With Sexually Transmitted Diseases or Blood-Borne Pathogens. Sexually Transmitted Diseases. 38(6). 522–527. 10 indexed citations
20.
Ma, Qiufei. (2009). Financial Resources, Living Arrangements, and Private Transfers. RAND Corporation eBooks. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lingling Yuan Breakdown of academic impact, for papers by Jie Guan Breakdown of academic impact, for papers by Christopher D. Clay Breakdown of academic impact, for papers by Afshin Rakhsha Breakdown of academic impact, for papers by Adam Goldman Breakdown of academic impact, for papers by Gaia Moretta Breakdown of academic impact, for papers by Tejaswi Mudigonda Breakdown of academic impact, for papers by Adrian YS Yip Breakdown of academic impact, for papers by Lorenzo Iovino Breakdown of academic impact, for papers by R. Izu
Rankless by CCL
2026